ATE437221T1 - Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie - Google Patents
Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapieInfo
- Publication number
- ATE437221T1 ATE437221T1 AT02751970T AT02751970T ATE437221T1 AT E437221 T1 ATE437221 T1 AT E437221T1 AT 02751970 T AT02751970 T AT 02751970T AT 02751970 T AT02751970 T AT 02751970T AT E437221 T1 ATE437221 T1 AT E437221T1
- Authority
- AT
- Austria
- Prior art keywords
- gene therapy
- vectors
- lentiviral vectors
- vectors encoding
- clotting factors
- Prior art date
Links
- 239000013598 vector Substances 0.000 title abstract 4
- 239000003114 blood coagulation factor Substances 0.000 title abstract 2
- 238000001415 gene therapy Methods 0.000 title abstract 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 title 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 title 1
- 108700019146 Transgenes Proteins 0.000 abstract 3
- 101000911390 Homo sapiens Coagulation factor VIII Proteins 0.000 abstract 2
- 241000713666 Lentivirus Species 0.000 abstract 2
- 102000057593 human F8 Human genes 0.000 abstract 2
- 229960000027 human factor ix Drugs 0.000 abstract 2
- 229960000900 human factor viii Drugs 0.000 abstract 2
- 208000031220 Hemophilia Diseases 0.000 abstract 1
- 208000009292 Hemophilia A Diseases 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000004806 packaging method and process Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10041—Use of virus, viral particle or viral elements as a vector
- C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29108301P | 2001-05-14 | 2001-05-14 | |
| PCT/US2002/015062 WO2002092134A1 (en) | 2001-05-14 | 2002-05-14 | Lentiviral vectors encoding clotting factors for gene therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE437221T1 true ATE437221T1 (de) | 2009-08-15 |
Family
ID=23118741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02751970T ATE437221T1 (de) | 2001-05-14 | 2002-05-14 | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US6808905B2 (de) |
| EP (1) | EP1395293B1 (de) |
| AT (1) | ATE437221T1 (de) |
| DE (1) | DE60233047D1 (de) |
| WO (1) | WO2002092134A1 (de) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1395293B1 (de) * | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
| JP2004283024A (ja) * | 2003-03-19 | 2004-10-14 | Junsei Chemical Co Ltd | 新規アンチセンスオリゴヌクレオチド及び抗ｈｉｖ剤 |
| GB0325379D0 (en) * | 2003-10-30 | 2003-12-03 | Oxford Biomedica Ltd | Vectors |
| PL2348114T3 (pl) | 2004-04-21 | 2019-08-30 | Alexion Pharmaceuticals, Inc. | Koniugaty do dostarczania do kości i sposób ich wykorzystania do nakierowywania białek na kość |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| DK1804839T3 (da) | 2004-09-22 | 2012-04-10 | St Jude Childrens Res Hospital | Forbedret ekspression af faktor ix i genterapivektorer |
| US8008468B2 (en) * | 2005-02-16 | 2011-08-30 | Benitec, Inc. | RNAi expression constructs with liver-specific enhancer/promoter |
| EP1928504B1 (de) * | 2005-08-19 | 2013-04-24 | University of Technology, Sydney | Gegen die leber gerichtete gentherapie |
| US8129510B2 (en) * | 2006-03-30 | 2012-03-06 | The Board Of Trustees Of The Leland Stanford Junior University | Minigene expression cassette |
| RS53302B (sr) | 2007-05-11 | 2014-08-29 | Alexion Pharma Holding | Alkalna fosfataza koja je usmerena na kosti, pribor i postupci upotrebe |
| DK2282764T3 (da) | 2008-04-22 | 2019-10-14 | Vib Vzw | Leverspecifikke nukleinsyreregulerende elementer samt fremgangsmåder og anvendelser heraf |
| EP2563406A4 (de) | 2010-04-30 | 2013-11-13 | Alexion Pharma Internat Sarl | Verfahren, zusammensetzungen und kits zur behandlung von matrixmineralisierungsstörungen |
| EP2658979B1 (de) | 2010-12-27 | 2018-02-14 | Alexion Pharmaceuticals, Inc. | Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür |
| WO2012143401A1 (en) * | 2011-04-18 | 2012-10-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Tissue-specific regulation of transgene expression |
| SG11201401605QA (en) | 2011-10-19 | 2014-09-26 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| FI3889173T3 (fi) | 2013-02-15 | 2023-10-02 | Bioverativ Therapeutics Inc | Optimoitu tekijä viii:n geeni |
| EP2994530A4 (de) | 2013-05-10 | 2016-11-16 | Whitehead Biomedical Inst | Proteinmodifizierung von lebenden zellen unter verwendung von sortase |
| WO2016004113A1 (en) | 2014-06-30 | 2016-01-07 | Biogen Ma Inc. | Optimized factor ix gene |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| WO2016090251A1 (en) | 2014-12-05 | 2016-06-09 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| US10603361B2 (en) | 2015-01-28 | 2020-03-31 | Alexion Pharmaceuticals, Inc. | Methods of treating a subject with an alkaline phosphatase deficiency |
| EP3283126B1 (de) | 2015-04-16 | 2019-11-06 | Emory University | Rekombinante promotoren und vektoren zur proteinexpression in leber und verwendung davon |
| AU2016308624B2 (en) | 2015-08-17 | 2022-06-23 | Alexion Pharmaceuticals, Inc. | Manufacturing of alkaline phosphatases |
| EP3355904A4 (de) | 2015-09-28 | 2019-06-12 | Alexion Pharmaceuticals, Inc. | Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie |
| JP2018533571A (ja) | 2015-10-30 | 2018-11-15 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 患者の頭蓋縫合早期癒合症を治療するための方法 |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| EP3426286A4 (de) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | Verfahren zur behandlung von hypophosphatasie bei kindern |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| KR20180125979A (ko) | 2016-04-01 | 2018-11-26 | 알렉시온 파마슈티칼스, 인코포레이티드 | 알칼리성 포스파타아제로 근육 약화의 치료 |
| EP3443001B1 (de) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | Regulierte bioschaltkreissysteme |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| JP7018933B2 (ja) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 気管気管支軟化症の治療方法 |
| CN110913954A (zh) | 2017-03-03 | 2020-03-24 | 黑曜石疗法公司 | 免疫疗法的组合物和方法 |
| CN110831961B (zh) | 2017-03-03 | 2024-01-02 | 黑曜石疗法公司 | 用于免疫疗法的cd19组合物和方法 |
| MX2019011508A (es) | 2017-03-31 | 2019-11-01 | Alexion Pharma Inc | Metodos para tratar la hipofosfatasia (hpp) en adultos y adolescentes. |
| BR112020002394A2 (pt) | 2017-08-09 | 2020-07-28 | Bioverativ Therapeutics Inc. | moléculas de ácidos nucleicos e usos das mesmas |
| JP7551496B2 (ja) | 2017-10-31 | 2024-09-17 | カリヴィル イムノセラピューティクス， インコーポレイテッド | 全身送達のためのプラットフォーム腫瘍溶解性ベクター |
| EP3728594A1 (de) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materialien und verfahren zur behandlung des usher-syndroms typ 2a |
| EP3728595A1 (de) | 2017-12-21 | 2020-10-28 | CRISPR Therapeutics AG | Materialien und verfahren zur behandlung des usher-syndroms des typs 2a und/oder von nichtsyndromaler autosomaler rezessiver retinitis pigmentosa (arrp) |
| AU2019215152A1 (en) | 2018-02-01 | 2020-08-20 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring PAH gene function and methods of use thereof |
| US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
| AU2019215063B2 (en) | 2018-02-01 | 2025-10-16 | Bioverativ Therapeutics, Inc. | Use of lentiviral vectors expressing Factor VIII |
| JP7244547B2 (ja) | 2018-02-19 | 2023-03-22 | ホモロジー・メディシンズ・インコーポレイテッド | Ｆ８遺伝子機能を回復させるためのアデノ随伴ウイルス組成物及びその使用の方法 |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| KR102925832B1 (ko) | 2018-08-09 | 2026-02-11 | 바이오버라티브 테라퓨틱스 인크. | 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도 |
| JP7820148B2 (ja) | 2018-08-10 | 2026-02-25 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼを用いて神経線維腫症１型および関連状態を治療する方法 |
| EP4461814A3 (de) * | 2018-10-12 | 2025-02-26 | Genzyme Corporation | Erzeugung von verbessertem menschlichem pah zur behandlung von schwerer pku durch lebergerichtete genersatztherapie |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| GB201818816D0 (en) * | 2018-11-19 | 2019-01-02 | Synpromics Ltd | Regulatory nucleic acid sequences |
| BR112021010047A2 (pt) | 2018-12-06 | 2021-08-24 | Bioverativ Therapeutics Inc. | Uso de vetores lentivirais expressando o fator ix |
| WO2020123716A1 (en) | 2018-12-11 | 2020-06-18 | Obsidian Therapeutics, Inc. | Membrane bound il12 compositions and methods for tunable regulation |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| CN114174327A (zh) | 2019-03-08 | 2022-03-11 | 黑曜石疗法公司 | 用于可调整调控的cd40l组合物和方法 |
| WO2020227515A1 (en) | 2019-05-07 | 2020-11-12 | Voyager Therapeutics, Inc. | Compositions and methods for the vectored augmentation of protein destruction, expression and/or regulation |
| WO2020252404A1 (en) | 2019-06-12 | 2020-12-17 | Obsidian Therapeutics, Inc. | Ca2 compositions and methods for tunable regulation |
| JP2022537670A (ja) | 2019-06-12 | 2022-08-29 | オブシディアン セラピューティクス， インコーポレイテッド | Ｃａ２の組成物および調整可能な制御方法 |
| KR20220047635A (ko) | 2019-08-23 | 2022-04-18 | 론자 워커스빌 아이엔씨. | 렌티바이러스 벡터의 생산을 위한 방법 및 작제물 |
| US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| MX2022002747A (es) | 2019-09-10 | 2022-04-06 | Obsidian Therapeutics Inc | Proteinas de fusion de ca2-il15 para regulacion ajustable. |
| US12403164B2 (en) | 2019-09-30 | 2025-09-02 | Bioverativ Therapeutics Inc. | Lentiviral vector formulations |
| JP7640538B2 (ja) | 2019-10-08 | 2025-03-05 | トラスティーズ オブ ボストン カレッジ | 複数の異なる非天然アミノ酸を含有するタンパク質、並びにそのようなタンパク質の製造方法及び使用方法 |
| CN114901297A (zh) * | 2019-10-16 | 2022-08-12 | 卡利威尔免疫治疗公司 | 用于原位产生逆转录病毒的生产者病毒 |
| MX2022007114A (es) | 2019-12-09 | 2022-07-11 | Alexion Pharma Inc | Polipeptidos de fosfatasa alcalina y metodos de uso de los mismos. |
| MX2022008415A (es) | 2020-01-08 | 2022-08-08 | Obsidian Therapeutics Inc | Composiciones y metodos para la regulacion ajustable de la transcripcion. |
| TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
| WO2021155323A1 (en) | 2020-01-31 | 2021-08-05 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines |
| AU2021357520A1 (en) | 2020-03-05 | 2022-09-29 | Neotx Therapeutics Ltd. | Methods and compositions for treating cancer with immune cells |
| TW202208632A (zh) | 2020-05-27 | 2022-03-01 | 美商同源醫藥公司 | 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法 |
| KR20230074703A (ko) | 2020-06-24 | 2023-05-31 | 바이오버라티브 테라퓨틱스 인크. | 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법 |
| US20220090130A1 (en) | 2020-08-23 | 2022-03-24 | Bioverativ Therapeutics Inc. | MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA) |
| MX2023002673A (es) | 2020-09-04 | 2023-05-12 | Alexion Pharma Inc | Métodos para el tratamiento de trastornos de mineralización ósea. |
| WO2022060806A1 (en) | 2020-09-16 | 2022-03-24 | Obsidian Therapeutics, Inc. | Compositions and methods for expression of anti-bcma chimeric antigen receptors with small molecule-regulated il15 in t cells |
| PE20231175A1 (es) | 2020-11-19 | 2023-08-01 | Kalivir Immunotherapeutics Inc | Inmunoterapia oncolitica por remodelacion del microambiente tumoral |
| EP4291224A4 (de) | 2021-02-12 | 2025-01-01 | Alexion Pharmaceuticals, Inc. | Alkalische phosphatasepolypeptide und verfahren zur verwendung davon |
| IL316712B2 (en) | 2021-04-30 | 2025-12-01 | Kalivir Immunotherapeutics Inc | Oncolytic viruses for modified mhc expression |
| CA3217862A1 (en) | 2021-05-05 | 2022-11-10 | Radius Pharmaceuticals, Inc. | Animal model having homologous recombination of mouse pth1 receptor |
| AU2022301302A1 (en) | 2021-07-01 | 2024-01-25 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and related methods |
| AU2022325955A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
| JP2024534771A (ja) | 2021-08-11 | 2024-09-26 | サナ バイオテクノロジー，インコーポレイテッド | 補体媒介性炎症反応を低減するための同種異系細胞療法のための遺伝子改変細胞 |
| JP2024531234A (ja) | 2021-08-11 | 2024-08-29 | サナ バイオテクノロジー，インコーポレイテッド | 同種異系細胞療法のための遺伝子改変された初代細胞 |
| WO2023019226A1 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
| JP2024534123A (ja) | 2021-08-23 | 2024-09-18 | バイオベラティブ セラピューティクス インコーポレイテッド | バキュロウイルス発現システム |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
| JP2025508720A (ja) | 2022-02-17 | 2025-04-10 | サナ バイオテクノロジー，インコーポレイテッド | 遺伝子操作されたｃｄ４７タンパク質及びその使用関連出願の相互参照 |
| US20250101382A1 (en) | 2022-03-11 | 2025-03-27 | Sana Biotechnology, Inc. | Genetically modified cells and compositions and uses thereof |
| CN120051297A (zh) | 2022-06-30 | 2025-05-27 | 因达普塔治疗公司 | 工程化自然杀伤(nk)细胞与抗体疗法的组合及相关方法 |
| US20260027145A1 (en) | 2022-07-27 | 2026-01-29 | Sana Biotechnology, Inc. | Methods of transduction using a viral vector and inhibitors of antiviral restriction factors |
| WO2024151541A1 (en) | 2023-01-09 | 2024-07-18 | Sana Biotechnology, Inc. | Type-1 diabetes autoimmune mouse |
| AU2024264889A1 (en) | 2023-05-03 | 2025-11-13 | Sana Biotechnology, Inc. | Methods of dosing and administration of engineered islet cells |
| CN121604968A (zh) | 2023-05-22 | 2026-03-03 | 萨那生物科技公司 | 递送胰岛细胞的方法及相关方法 |
| WO2025226943A1 (en) | 2024-04-25 | 2025-10-30 | Masonic Medical Research Laboratory | Polynucleotide for hepatocyte expression of vestigial like protein 4 and method of use thereof |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US650309A (en) * | 1899-08-07 | 1900-05-22 | William Denham | Machine for filling bottles. |
| US5716826A (en) | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| FR2629469B1 (fr) | 1988-03-31 | 1990-12-21 | Pasteur Institut | Retrovirus recombinant defectif, son application a l'integration de sequences codantes pour des proteines determinees dans le genome de cultures cellulaires infectables par le retrovirus sauvage correspondant et adns recombinants pour la production de ce retrovirus recombinant |
| US5614404A (en) | 1988-06-10 | 1997-03-25 | Theriod Biologics, Incorporated | Self-assembled, defective, non-self-propagating lentivirus particles |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| CA2557882C (en) | 1992-02-28 | 2010-05-18 | Syngenix Limited | Defective packaging non-oncoviral vectors based on mpmv and hiv |
| US5834256A (en) | 1993-06-11 | 1998-11-10 | Cell Genesys, Inc. | Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| AU2419595A (en) | 1994-05-10 | 1995-11-29 | Hisamitsu Pharmaceutical Co., Inc. | Recombinant human immunodeficiency virus vector and process for producing the same |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| US5681746A (en) | 1994-12-30 | 1997-10-28 | Chiron Viagene, Inc. | Retroviral delivery of full length factor VIII |
| US5650309A (en) | 1995-05-16 | 1997-07-22 | The Regents Of The University Of California | Viral vectors |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5750383A (en) | 1996-05-14 | 1998-05-12 | Boyce Thompson Institute For Plant Research, Inc. | Baculovirus cloning system |
| AU4340397A (en) | 1996-09-11 | 1998-04-02 | Biogen, Inc. | Non-mammalian dna virus having an altered coat protein |
| CA2265522A1 (en) | 1996-09-17 | 1998-03-26 | The Salk Institute For Biological Studies | Retroviral vectors capable of transducing non-dividing cells |
| US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
| EP1003894A2 (de) | 1997-07-18 | 2000-05-31 | Chiron Corporation | Lentivirale vektoren |
| US5994136A (en) * | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| AU778698B2 (en) * | 1999-04-29 | 2004-12-16 | Miltenyi Biotec B.V. & Co. KG | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US7077837B2 (en) * | 2000-11-20 | 2006-07-18 | Implant Sciences Corporation | Multi-layered radiopaque coating on intravascular devices |
| EP1395293B1 (de) * | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie |
-
2002
- 2002-05-14 EP EP02751970A patent/EP1395293B1/de not_active Expired - Lifetime
- 2002-05-14 AT AT02751970T patent/ATE437221T1/de not_active IP Right Cessation
- 2002-05-14 WO PCT/US2002/015062 patent/WO2002092134A1/en not_active Ceased
- 2002-05-14 DE DE60233047T patent/DE60233047D1/de not_active Expired - Lifetime
- 2002-05-14 US US10/145,289 patent/US6808905B2/en not_active Expired - Lifetime
-
2004
- 2004-07-06 US US10/885,457 patent/US7179903B2/en not_active Expired - Lifetime
-
2007
- 2007-01-23 US US11/626,192 patent/US7745179B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US6808905B2 (en) | 2004-10-26 |
| EP1395293B1 (de) | 2009-07-22 |
| WO2002092134A8 (en) | 2003-02-27 |
| WO2002092134A1 (en) | 2002-11-21 |
| US7745179B2 (en) | 2010-06-29 |
| EP1395293A1 (de) | 2004-03-10 |
| US7179903B2 (en) | 2007-02-20 |
| US20070178592A1 (en) | 2007-08-02 |
| EP1395293A4 (de) | 2006-06-07 |
| US20030077812A1 (en) | 2003-04-24 |
| US20040259208A1 (en) | 2004-12-23 |
| DE60233047D1 (de) | 2009-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60233047D1 (de) | Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie | |
| YU71002A (sh) | Proizvodnja rekombinantnih faktora koagulacije krvi u humanim ćelijama | |
| MX9606386A (es) | Agentes que afectan la hemostasis trombotica. | |
| MXPA05013564A (es) | Proteinas de fusion. | |
| DE60225118D1 (de) | Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden | |
| ATE529444T1 (de) | Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten | |
| ATE240744T1 (de) | Verwendung von csf-1-inhibitoren | |
| CY1111626T1 (el) | ΠΑΡΑΛΛΑΓΕΣ ΠΟΛΥΠΕΠΤΙΔΙΩΝ ΠΑΡΑΓΟΝΤΑ VII ´H VIIa | |
| ATE454403T1 (de) | Menschliche koagulationsfaktor vii polypeptide | |
| MXPA03001984A (es) | Variantes de factor vii de coagulacion humano. | |
| FR2830451B1 (fr) | Utilisation de peptides analogues de la thymuline(pat)pour la fabrication de medicaments contre la douleur | |
| GB0100551D0 (en) | Protein | |
| ATE323153T1 (de) | Sphingosinekinase | |
| CY1112957T1 (el) | Μη νευροτοξικοι παραγοντες, οι οποιοι ενεργοποιουν το πλασμινογονο για τη θεραπευτικη αγωγη εγκεφαλικου επεισοδιου | |
| ATE457359T1 (de) | Auf lps-reagierendes chs1/beige-ähnliches anker- gen und therapeutische anwendungen davon | |
| ATE368455T1 (de) | Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz | |
| ATE417618T1 (de) | Faktor-viii-polypeptide auf hohem expressionsniveau codierende nukleinsäure- und aminosäuresequenzen und verwendungsverfahren | |
| GB2368846A (en) | A lung cancer associated retrovirus gene delivery vector and methods of use th ereof | |
| HUP9900789A2 (hu) | Lefelé irányuló szabályozásra rezisztens C3 konvertáz | |
| ATE328082T1 (de) | Verkürztes bard1 protein und dessen diagnostische und therapeutische anwendungen | |
| WO2000017375A3 (en) | Method to treat haemophilia by in vivo gene therapy with retroviral vectors | |
| GR1003885B (el) | Μη-πεπτιδικοι μιμητες της δραστικης αλληλουχιας s42fllr46 του υποδοχεα της θρομβινης για την θεραπεια της θρομβωσης και του καρκινου | |
| ATE360062T1 (de) | Deglykosilierte fragmente der kringle 1-5 region von plasminogen und verwendungsverfahren |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |